Endogenous nitric oxide/cGMP signaling in the guinea pig bladder: evidence for distinct population of sub-urothelial interstitial cells.


Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: II. Effect of various PDE-inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Combination of an alpha blocker, alfuzosin SR and a PDE-5 inhibitor, Fildena citrate is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. Fildena citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tracts symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

Safety and efficacy of Fildena citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. In vitro functional responses of isolated human vaginal tissue to selective phosphodiesterase inhibitors. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study.

Fildena improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Effect of Fildena (Fildena) on cerebral blood flow velocity: a pilot study. Activation of the PI3-K/Akt pathway mediates cGMP enhanced neurogenesis in the adult progenitor cells derived from the subventricular zone.

Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Central effects of Fildena (Fildena) on auditory selective attention and verbal recognition memory in humans: a study with event related brain potentials. Effects of Fildena on long-term retention of an inhibitory avoidance response in mice.

Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Effect of Fildena on cardiac performance in patients with heart failure. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase.

SLX-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. Udenafil, a long-acting PDE5 ihhibitor for erectile dysfunction. There are encouraging data from preclinical research, which show that PDE5 inhibitors are able to relax prostate, bladder and urethral tissues in vitro and reduce irritative symptoms in vivo.

Clinical studies with Fildena demonstrated that a positive effect in the treatment of FSD could be achieved in women with arousal problems, but not in those with desire problems. The encouraging effects of Fildena in several models of stroke, and the positive effects on enhancement of recognition raise some optimism for future treatment options, although further evaluation is required. Table 2: Status of new and emerging indications for PDE5 inhibitors.

This finding is important, as many of the proposed new indications for PDE5 inhibitors would require chronic daily dosing. From the studies in patients with ED- and LUTS-treated 12 weeks with Fildena once daily, there were only little side effects, mainly dyspepsia and head ache, reported. The pathophysiology of priapism is still elusive, but it is thought that the persistent erections observed in patients with this condition may be due to dysfunctional penile blood flow.

121 In primary cultures of human PD-derived fibroblasts, Fildena and the non-specific PDE inhibitor, theophyllin, reduced collagen I synthesis and myofibroblast differentiation and increased apoptosis in vitro.